Abbott Laboratories - Free Cash Flow To Equity

Abbott Laboratories's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Free-Cash-Flow-To-Equity" stands at 4.76 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025.

Abbott Laboratories's third quarter result of 1.80 Billion USD for the item "Free Cash Flow To Equity" represents an increase of 17.52 percent compared to it's second quarter result.

Also, Abbott Laboratories's third quarter result of 1.80 Billion USD for the item "Free Cash Flow To Equity" represents a decrease of -17.97 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Abbott Laboratories's third quarter result of 4.76 Billion USD for the item "Free Cash Flow To Equity" represents a decrease of -7.64 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an increase of 4.75 Billion United States Dollars compared to the value the year prior.
The 1 year change is 4.75 Billion United States Dollars.
The 3 year change is -2.88 Billion United States Dollars.
The 5 year change is 1.35 Billion United States Dollars.
The 10 year change is 2.61 Billion United States Dollars.

The Serie's long term average value is 4.68 Billion United States Dollars. It's latest available value, on 09/30/2025, is 0.076 Billion United States Dollars higher, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 12/31/2018, to it's latest available value, on 09/30/2025, is +8.30 Billion.
The Serie's change in United States Dollars from it's maximum value, on 12/31/2016, to it's latest available value, on 09/30/2025, is -10.34 Billion.